Crescita Reports Q4 and Fiscal 2025 Results

• The most recent release (March 31, 2026) reports Q4 and full-year 2025 financial results alongside confirmation of the definitive acquisition by ClinActiv Holdings.
• FY2025 revenue grew 7.9% to $21.118M, with gross margin expanding to 52.6%. The company swung to a near-breakeven net loss of $92k, a significant improvement from the $2.75M loss in FY2024.
• The acquisition terms remain unchanged from the March 16 announcement: all-cash offer of $0.80 per share (minimum $0.75), representing a ~74% premium to the pre-announcement five-day VWAP.
• Operational updates include a lease extension through 2031, a $775k cash acquisition of Laboratoire Provence-Canada assets, a €575k termination payment from Croma Pharma, and an exclusive five-year manufacturing supply agreement.
• Post-closing, the transaction will split the company: ClinActiv acquires the commercial skincare and contract manufacturing business, while senior management retains remaining assets.

• The acquisition provides a definitive liquidity event at a premium, fundamentally altering the investment thesis from operational turnaround to deal execution.
• Financial improvements are real but partially driven by non-recurring items, specifically the €575k Croma termination payment and working capital timing. Core operating profitability remains thin.
• The premium is calculated against a depressed trading base, and the deal includes a working capital adjustment mechanism that could reduce the final per-share payout.
• The post-closing carve-out introduces structural complexity and potential value leakage, as management retains unspecified "remaining assets" while shareholders receive cash only for the core business.
• Given the March 16 announcement, this release is largely confirmatory. The market impact is positive but incremental, as the acquisition terms are already public and priced into expectations.

• Crescita operates a dual-segment business: commercial skincare products and contract manufacturing (CMO) for topical pharmaceuticals and cosmetics.
• Flagship asset: Pliaglis® topical anesthetic. Rights were regained in eight territories following the mutual termination of the Croma Pharma licensing agreement.
• The manufacturing division has become the primary growth driver, recently expanded through the acquisition of Laboratoire Provence-Canada assets and a new five-year exclusive supply contract.
• The company is transitioning from a standalone biopharma/skincare operator to a target for strategic consolidation in the dermatology and CMO space.